Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk..
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291266 | PMC |
| http://dx.doi.org/10.1158/1078-0432.CCR-20-0462 | DOI Listing |
Publication Analysis
Top Keywords
hi's lo's
4
lo's cytarabine
4
cytarabine acute
4
acute myeloid
4
myeloid leukemia
4
leukemia cytarabine
4
cytarabine backbone
4
backbone aml
4
aml therapy
4
therapy dose
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!